Lyka Labs Amalgamation Effective: Authorised Capital Surges to ₹59 Crore

Lyka Labs Limited's authorized share capital has been boosted to ₹59.00 crore following the completion of its merger with Lyka Exports Limited. The integration officially became effective on April 8, 2026.

What just happened

This critical step, which received approval from the National Company Law Tribunal (NCLT) on March 16, 2026, officially combines Lyka Labs and Lyka Exports.

With the merger now effective, Lyka Labs' authorized share capital has expanded to ₹59.00 crore. This total includes 5.70 crore equity shares and 2.00 lakh preference shares, now encompassing Lyka Exports' absorbed capital. Lyka Labs' Memorandum of Association has been updated to reflect this significant increase, formalizing the integration.

Why this matters

This merger is a strategic move by Lyka Labs to simplify its corporate structure, combine similar business activities, and achieve greater economies of scale. By consolidating operations, the company expects to boost operational efficiency, improve financial strength, and reduce costs through streamlined processes and administrative expenses.

The integrated company aims for greater financial flexibility, better cash management, and improved access to various market segments. Ultimately, the goal is to maximize shareholder value and strengthen Lyka Labs' competitive position in the pharmaceutical sector.

The backstory

The path to this effective date has been extensive. The NCLT's approval on March 16, 2026, was a key milestone. The merger's appointed date was set earlier, on April 1, 2022, highlighting the numerous regulatory and procedural steps. Lyka Labs, known for its WHO-GMP and ISO 9001 certifications in pharmaceutical formulations and APIs, has prior experience with corporate restructuring, including a 2016 merger involving Lyka Healthcare Ltd. and Lyka Exports Limited.

What changes now

• One Company: Lyka Exports Limited will no longer exist as a separate entity. Lyka Labs Limited will be the sole surviving company.
• Larger Capital Base: Lyka Labs' authorized share capital now stands at ₹59.00 crore, up from its previous level.
• Transfer of Assets and Liabilities: All assets, properties, rights, liabilities, and duties of Lyka Exports will transfer to Lyka Labs.
• Smoother Operations: The combined company anticipates benefits from greater integration, improved efficiency, and cost savings.
• Employee Transition: Employees of Lyka Exports will join Lyka Labs, maintaining similar employment terms.

Risks to watch

Despite this structural consolidation, Lyka Labs faces significant challenges. The company has reported declining earnings and is currently unprofitable, with losses growing over the past five years. Lyka Labs' stock performance has also been weak, showing a negative 1-year return of -44.12%. The company also previously settled a GST audit matter involving over ₹15 lakh. Successful integration and a turnaround in financial performance will be critical for the combined entity.

Peer comparison

Lyka Labs operates in the highly competitive Indian pharmaceutical sector, which includes major players like Sun Pharma, Divi's Laboratories, and Torrent Pharma. While direct comparisons for an amalgamation event are limited, the industry overall is seeing growth, even as Lyka Labs navigates its internal restructuring and profitability issues.

What to track next

• Integration Progress: Monitor how smoothly Lyka Labs integrates Lyka Exports' operations and achieves its projected cost savings.
• Financial Performance: Look for improvements in revenue, profitability, and margins following the merger, especially given the company's current unprofitability.
• Shareholder Value: Assess the impact of the combined entity on overall shareholder returns and market valuation.
• Regulatory Compliance: Ensure continued adherence to all post-merger regulatory requirements.
• Market Position: Observe if the combined entity can leverage its scaled operations to gain greater market share or enter new segments.